U.S., May 19 -- ClinicalTrials.gov registry received information related to the study (NCT07593573) titled 'the Exploration of MTAP Deletion in Osteosarcoma by Immunohistochemistry' on May 12.
Brief Summary: MTAP deletion frequently occurs in osteosarcoma, and PRMT5 has been identified as a synthetic lethal target for cancers with homozygous deletion of the MTAP gene, making it a promising target for anti-tumor drug development.This study aims to evaluate the overall status of MTAP deficiency in the tissues of osteosarcoma patients and its correlation with clinical features such as metastasis and immune subtypes by examining the MTAP protein expression levels in previous histological samples of the patients and combining this with their cl...